Brittenham Marissa 4

What Happened
Marissa Brittenham, Chief Strategy Officer of Surgery Partners, sold 3,657 shares on March 13, 2026 at $12.54 per share, yielding proceeds of $45,859. This was a sale (coded S) rather than a purchase—consistent with a routine sell-to-cover transaction tied to equity vesting.

Key Details

• Transaction date: March 13, 2026; Filing date: March 16, 2026 (reporting period 3/13/2026).
• Price and amount: 3,657 shares at $12.54 each; total proceeds $45,859.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: F1 — shares were sold to satisfy the reporting person’s tax withholding obligations in connection with restricted stock that vested on March 4, 2026 (a sell-to-cover).
• Transaction codes: S = Sale; F = Tax withholding.
• Filing timeliness: filed March 16, 2026; no late-filing indication in the supplied record (appears within the standard two-business-day window).

Context
The sale was executed to satisfy tax withholding from vested restricted stock, a common administrative action and not necessarily a signal about the insider’s view of the company. For retail investors, purchases by insiders are generally more informative than routine sell-to-cover transactions.